Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VIR-2482 for Prevention of Influenza A
NCT04033406Phase 1Completed
- Sponsor
- Vir Biotechnology
- Start
- Aug 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Influenza A (IAV) comparing VIR-2482 with Placebo (2 arms). Primary endpoints: Number of participants with treatment-emergent adverse events at 12 months, Number of participants with abnormalities in vital signs at 12 months and 2 more. Started Aug 2019; status: completed.
02
Drugs
VIR-2482
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT04033406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033406.